CareDx, Inc (NASDAQ:CDNA) Shares Bought by Two Sigma Investments LP

Two Sigma Investments LP grew its holdings in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 468,836 shares of the company's stock after buying an additional 156,312 shares during the quarter. Two Sigma Investments LP owned 0.87% of CareDx worth $10,038,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sterling Capital Management LLC boosted its holdings in CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company's stock valued at $27,000 after acquiring an additional 1,126 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of CareDx by 553.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company's stock worth $84,000 after purchasing an additional 3,322 shares during the last quarter. State of Wyoming bought a new stake in shares of CareDx during the fourth quarter worth $91,000. Plato Investment Management Ltd boosted its stake in shares of CareDx by 34.1% during the fourth quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock valued at $116,000 after purchasing an additional 1,370 shares during the period. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd grew its holdings in shares of CareDx by 41.5% in the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock worth $200,000 after purchasing an additional 2,742 shares during the last quarter.

CareDx Stock Up 2.4%

CDNA stock traded up $0.40 during trading on Friday, hitting $16.96. 116,602 shares of the company's stock traded hands, compared to its average volume of 893,484. The firm has a market capitalization of $944.07 million, a P/E ratio of -6.29 and a beta of 2.27. CareDx, Inc has a 1 year low of $12.90 and a 1 year high of $34.84. The business has a fifty day simple moving average of $17.32 and a two-hundred day simple moving average of $20.58.

CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business's revenue was up 17.6% compared to the same quarter last year. During the same period last year, the business posted ($0.03) EPS. On average, equities research analysts predict that CareDx, Inc will post -0.9 EPS for the current fiscal year.

Insider Buying and Selling at CareDx

In other news, Director Christine Cournoyer sold 16,700 shares of the stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $14.13, for a total transaction of $235,971.00. Following the completion of the sale, the director now owns 37,045 shares in the company, valued at approximately $523,445.85. This represents a 31.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Peter Maag sold 13,281 shares of the firm's stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the completion of the sale, the director now directly owns 316,743 shares of the company's stock, valued at $5,457,481.89. The trade was a 4.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 59,382 shares of company stock worth $934,509 over the last quarter. Insiders own 4.90% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on CDNA. The Goldman Sachs Group lowered their price objective on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research report on Thursday, April 17th. HC Wainwright reiterated a "neutral" rating and issued a $25.00 price target on shares of CareDx in a report on Monday, May 5th. Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Finally, Stephens reaffirmed an "overweight" rating and set a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.